Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors
Arthritis Research & Therapy2012Vol. 14(6), pp. R253–R253
Citations Over TimeTop 10% of 2012 papers
Katelin Haynes, Allison R. Pettit, Ran Duan, Hsu‐Wen Tseng, Tibor T. Glant, Matthew A. Brown, Gethin Thomas
Abstract
This study implicates the Wnt pathway as a likely mediator of the mechanism by which inflammation induces bony ankylosis in spondyloarthritis, raising the potential that therapies targeting this pathway may be effective in preventing this process.
Related Papers
- → Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome(2013)78 cited
- → The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5(2015)48 cited
- → LRP5: From bedside to bench to bone(2017)42 cited
- → Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume(2018)11 cited
- → Changes in expression of Wnt signaling pathway inhibitors dickkopf-1 and sclerostin before and after total joint arthroplasty(2017)5 cited